» Articles » PMID: 36818162

Identification of Pyroptosis-Relevant Signature in Tumor Immune Microenvironment and Prognosis in Skin Cutaneous Melanoma Using Network Analysis

Overview
Journal Stem Cells Int
Publisher Wiley
Specialty Cell Biology
Date 2023 Feb 23
PMID 36818162
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pyroptosis is closely related to the programmed death of cancer cells as well as the tumor immune microenvironment (TIME) via the host-tumor crosstalk. However, the role of pyroptosis-related genes as prognosis and TIME-related biomarkers in skin cutaneous melanoma (SKCM) patients remains unknown.

Methods: We evaluated the expression profiles, copy number variations, and somatic mutations (CNVs) of 27 genes obtained from MSigDB database regulating pyroptosis among TCGA-SKCM patients. Thereafter, we conducted single-sample gene set enrichment analysis (ssGSEA) for evaluating pyroptosis-associated expression patterns among cases and for exploring the associations with clinicopathological factors and prognostic outcome. In addition, a prognostic pyroptosis-related signature (PPRS) model was constructed by performing Cox regression, weighted gene coexpression network analysis (WGCNA), and least absolute shrinkage and selection operator (LASSO) analysis to score SKCM patients. On the other hand, we plotted the ROC and survival curves for model evaluation and verified the robustness of the model through external test sets (GSE22153, GSE54467, and GSE65904). Meanwhile, we examined the relations of clinical characteristics, oncogene mutations, biological processes (BPs), tumor stemness, immune infiltration degrees, immune checkpoints (ICs), and treatment response with PPRS via multiple methods, including immunophenoscore (IPS) analysis, gene set variation analysis (GSVA), ESTIMATE, and CIBERSORT. Finally, we constructed a nomogram incorporating PPRS and clinical characteristics to improve risk evaluation of SKCM.

Results: Many pyroptosis-regulated genes showed abnormal expression within SKCM. TP53, TP63, IL1B, IL18, IRF2, CASP5, CHMP4C, CHMP7, CASP1, and GSDME were detected with somatic mutations, among which, a majority displayed CNVs at high frequencies. Pyroptosis-associated profiles established based on pyroptosis-regulated genes showed markedly negative relation to low stage and superior prognostic outcome. Blue module was found to be highly positively correlated with pyroptosis. Later, this study established PPRS based on the expression of 8 PAGs (namely, GBP2, HPDL, FCGR2A, IFITM1, HAPLN3, CCL8, TRIM34, and GRIPAP1), which was highly associated with OS, oncogene mutations, tumor stemness, immune infiltration degrees, IC levels, treatment responses, and multiple biological processes (including cell cycle and immunoinflammatory response) in training and test set samples.

Conclusions: Based on our observations, analyzing modification patterns associated with pyroptosis among diverse cancer samples via PPRS is important, which can provide more insights into TIME infiltration features and facilitate immunotherapeutic development as well as prognosis prediction.

Citing Articles

Exploring the clinical and biological significance of the cell cycle-related gene CHMP4C in prostate cancer.

Xiao X, Li Z, Li Q, Qing L, Wang Y, Ye F BMC Med Genomics. 2024; 17(1):210.

PMID: 39138470 PMC: 11323463. DOI: 10.1186/s12920-024-01970-z.


Hyaluronic Acid Interacting Molecules Mediated Crosstalk between Cancer Cells and Microenvironment from Primary Tumour to Distant Metastasis.

Xu Y, Benedikt J, Ye L Cancers (Basel). 2024; 16(10).

PMID: 38791985 PMC: 11119954. DOI: 10.3390/cancers16101907.


Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma.

Chen W, He Y, Zhou G, Chen X, Ye Y, Zhang G BMC Med. 2024; 22(1):24.

PMID: 38229080 PMC: 10792919. DOI: 10.1186/s12916-023-03175-0.


System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma.

Zhao S, Zhu Y, Liu H, He X, Xie J J Transl Med. 2023; 21(1):801.

PMID: 37950289 PMC: 10636830. DOI: 10.1186/s12967-023-04513-9.

References
1.
Ogata D, Namikawa K, Takahashi A, Yamazaki N . A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021; 51(5):671-674. DOI: 10.1093/jjco/hyab022. View

2.
Lian Q, Yan S, Yin Q, Yan C, Zheng W, Gu W . TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity. Cell Mol Immunol. 2020; 18(2):350-362. PMC: 8027410. DOI: 10.1038/s41423-020-0366-2. View

3.
Mei Y, Chen M, Liang H, Ma L . A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. Commun Biol. 2021; 4(1):383. PMC: 7985195. DOI: 10.1038/s42003-021-01911-x. View

4.
Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

5.
Tian Q, Gao H, Zhao W, Zhou Y, Yang J . Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma. Future Oncol. 2021; 17(31):4115-4129. DOI: 10.2217/fon-2021-0104. View